E-DRUG: Survey - Access to new COVID-19 Therapeutics
----------------------------------------------------------------------------
Dear colleagues,
Apologies for cross-posting
Access to medicines has long been a challenge in many low-resource
settings, and the COVID-19 era has been no exception. The innovations in
COVID-19 R&D have moved by leaps and bounds, with many researchers,
scientists, and pharma at the forefront of developing new drugs to treat
and prevent COVID-19 infection and disease progression.
Some of these drugs have shown efficacy and have been granted regulatory
approval. Basing on the COVID-19 Clinical Research Coalition
<https://covid19crc.org/>'s principle of advocating for equal access to
innovations by all, and in advance of a related webinar planned for later
this year, the coalition would like to carry out a quick survey to assess
the access to these new medicines in different countries.
FILL OUT THE SURVEY <https://forms.office.com/r/QU1HAX8nB1>
Kind regards
Laila Harras-Pelletier
Graduate - Public Policy, Global Health
Project Associate Consultant @DND*i* <https://dndi.org/>
laila.harraspelletier@sciencespo.fr